Champions Oncology Reports Record Quarterly Revenue of $9.0 Million

The Children’s Cancer Therapy Development Institute is Collaborating with Champions Oncology and Jackson Laboratory to provide RACEact/PREA Pediatric Cancer Study Plan Services

Champions Oncology and PhenoVista Biosciences Announce a Strategic Partnership to provide Oncology Imaging-Based Phenotypic Assays for Preclinical Drug Development

Champions Oncology Partners with TransCure bioServices to Expand European Business and Operations

Champions Oncology Reports Record Quarterly Revenue of $6.2 Million

Champions Oncology Granted Full Accreditation by the AAALAC

Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018

Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies

Champions Oncology to Present at the 3rd Annual Disruptive Growth & Healthcare Conference on May 9th

Champions Oncology Adds Amy Wesa, Ph.D, as Director of Immuno-Oncology Research

Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House

Champions Oncology Reports Quarterly Revenue of $5.1 Million

Champions Oncology to Participate at the 30th Annual ROTH Conference

Motivated Patients with ROS1 Cancer Initiate Global Research Study

Champions Oncology Reports Record Quarterly Revenue of $5.2 Million

Champions Oncology announces $2 million award from the National Cancer Institute (NCI) to develop and evaluate prostate cancer PDX models

Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft (PDX) model responses and patient responses to oncology therapies

Champions Oncology Reports Record Quarterly Revenue of $5 Million

Champions Oncology Announces Strategic Collaboration with AstraZeneca to Develop Unique Cohorts of Patient-Derived Xenograft (PDX) Models

Champions Oncology Announces Research Collaboration with The Addario Lung Cancer Medical Institute to Develop Unique Cohort of Patient-Derived Xenograft (PDX) Models

Champions Oncology Reports 38% Revenue Growth

Champions Oncology Reports 40% Revenue Growth

Champions Oncology Announces Plan to Open New Lab Facility in Rockville, Maryland

Champions Oncology Announces New Collection of Patient-Derived Xenograft (PDX) Models Available for Translational Research

Champions Oncology Retains Hayden IR to Execute Comprehensive Investor Relations Program

Champions Oncology Reports 50% Revenue Growth, Accelerated Progress on Path to Profitability and Future Role Changes of the Senior Leadership

Champions Oncology Signs $2 million Contract

Champions Oncology Beats Revenue Guidance for Quarter; Reaffirms Full Year Guidance of 43 - 60% Revenue Growth

Champions Oncology Announces Revenue Up 26%, Projects 43% - 60% Growth For Current Fiscal Year

Champions Oncology to Announce Year-End 2016 Financial Results on Thursday, July 28, 2016

Champions Oncology Successfully Delivers First AML Study

Champions Oncology, Inc. Announces Closing of Public Offering of Common Stock

Champions Oncology, Inc. Announces Pricing of Public Offering of Common Stock

Champions Oncology Announces Addition to Board of Directors

Champions Oncology Reports Results for the Third Quarter Ended January 31, 2016

Champions To Present at the 28th Annual ROTH Capital Conference on March 16, 2016

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2016

Champions Oncology to Host Webinar on Patient-Derived Xenograft Program for Clinical Advancement

Champions Oncology Announces Initiation of Prospective Correlative Trial in Sarcoma